BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market

$2.4 Million in H1 2026 Capital Raises Ahead of Phase 3b ENDURANCE Trial NEW YORK, May 19, 2026 /PRNewswire/ --  May 19, 2026 – BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that in May it entered into definitive agreements for a private placement yielding gross proceeds of $400,000. Transaction Highlights and Premium Pricing: The transactions were priced at $0.95 per share, representing a 37.6% premium over the previous day's closing price of $0.69.